Oncodesign SA Offers World’s Most Comprehensive Collection of Patient-Derived Colorectal Tumor Models
Published: Mar 29, 2011
“This collection is the result of a five year research program, and is the most comprehensive worldwide in terms of the range of genetic heterogeneity and characterization. It marks a breakthrough in the evaluation of colorectal cancer therapies,” explained Philippe Genne, president and CEO of Oncodesign. “The CReMEC collection ensures low-passage experimental models to fit the clinical reality. This is all the more relevant since preclinical research usually relies on cell lines that may be many years old, grown in tissue culture and then grafted onto mice. Cell lines may drift into different genetic profiles and are not reliable enough to evaluate anticancer therapies.”
CReMEC brings together highly qualified and complementary skills from world-class French institutes, three pharmaceutical companies, and Oncodesign as project leader. The EUR 5.4 million program has been developed to meet industrial requirements and strict guidelines were observed from conception to characterization. A full range of characterization is available with each model. Clinical, molecular, pharmacological and histological data have been carefully collected and gathered in a dedicated database, in parallel with a biobank of more than 5,000 samples. The CReMEC collection and derivatives represent a valued basis for Oncodesign’s clients and academic institutions now conducting research projects with these resources.
Based on this initial success, Oncodesign says the consortium is considering the development of a dedicated national platform. The challenge is to provide patient-derived cancer models for any cancer pathology to meet unsatisfied needs in cancer research.
Oncodesign Biotechnology is dedicated to the discovery of effective anti-cancer therapies. Its strategic focus is two-fold: experimentation towards new anti-cancer therapies and implementation of discovery programs in partnership with the pharmaceutical industry. Oncodesign’s prime areas of expertise cover pharmacology, imaging and medicinal chemistry together with rigorous project management.
Oncodesign’s experimentation activity covers three complementary modules: the development of experimental in vivo chimeric models (patient-derived models and reconstituted human immune system models) in its Chi-Mice(R) module; non-invasive, multi-modal pharmaco-imaging (SPECT, MRI, PET) and biomarker identification and validation in its activities with the PharmImage(R) consortium which it leads; conventional in vitro and in vivo pharmacology for early proof of concept evaluation. Oncodesign markets a wide range of products and services based on these three areas of technological know-how for the validation of anticancer therapies.
The drug and imaging biomarker discovery activity at Oncodesign is based on its chemistry technology, Nanocyclix(R) for the synthesis and optimization of new compounds for therapeutic or diagnostic use. Nanocyclix (R) gives access to potent and selective kinase inhibitors with good drug-like properties. Coupled with Oncodesign’s three other technological specialties, Nanocyclix(R) enables Oncodesign to offer its partners a unique innovative platform applicable from target to patient in a risk-sharing relationship.
Founded in 1995, and led by Dr Philippe Genne, Oncodesign is based in Dijon, France. It employs 55 people including 14 PhDs. Dr Jan Hoflack was appointed as Chief Scientific Officer in 2009. The company is the European leader in pre-clinical evaluation of anticancer therapies.
For more information, see: http://www.oncodesign.com.
Mark Tidmarsh ANDREW LLOYD & ASSOCIATES http://www.ala.com firstname.lastname@example.org
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION